Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature
Luigi Carlo Turco, Francesco Cosentino, Gabriella Ferrandina(Agostino Gemelli University Polyclinic), Virginia Vargiu(Agostino Gemelli University Polyclinic), Serena Cappuccio(Agostino Gemelli University Polyclinic), Giuseppina Sallustio(Università Cattolica del Sacro Cuore), Anna Fagotti(Università Cattolica del Sacro Cuore), Giovanni Scambia(Agostino Gemelli University Polyclinic)
Cited by 10
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Outcome of Cesarean scar pregnancy managed expectantly: systematic review and meta‐analysis
|Ultrasound in Obstetrics and Gynecology|2017|299
SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer
|International Journal of Gynecological Cancer|2020|298